image: A rhenium-based complex developed at Rice University binds to fibrils of misfolded amyloid beta peptide, which marks the location of a hydrophobic cleft that could serve as a drug target, and oxidizes the fibril, which changes its chemistry in a way that could prevent further aggregation. view more
Credit: Martí Group/Rice University
HOUSTON -- (Oct. 19, 2017) -- A probe invented at Rice University that lights up when it binds to a misfolded amyloid beta peptide -- the kind suspected of causing Alzheimer's disease -- has identified a specific binding site on the protein that could facilitate better drugs to treat the disease.
Even better, the lab has discovered that when the metallic probe is illuminated, it catalyzes oxidation of the protein in a way they believe might keep it from aggregating in the brains of patients.
The study done on long amyloid fibrils backs up computer simulations by colleagues at the University of Miami that predicted the photoluminescent metal complex would attach itself to the amyloid peptide near a hydrophobic (water-avoiding) cleft that appears on the surface of the fibril aggregate. That cleft presents a new target for drugs.
Finding the site was relatively simple once the lab of Rice chemist Angel Martí used its rhenium-based complexes to target fibrils. The light-switching complex glows when hit with ultraviolet light, but when it binds to the fibril it becomes more than 100 times brighter and causes oxidation of the amyloid peptide.
"It's like walking on the beach," Marti said. "You can see that someone was there before you by looking at footprints in the sand. While we cannot see the rhenium complex, we can find the oxidation (footprint) it produces on the amyloid peptide.
"That oxidation only happens right next to the place where it binds," he said. "The real importance of this research is that allows us to see with a high degree of certainty where molecules can interact with amyloid beta fibrils."
The study appears in the journal Chem.
"We believe this hydrophobic cleft is a general binding site (on amyloid beta) for molecules," Martí said. "This is important because amyloid beta aggregation has been associated with the onset of Alzheimer's disease. We know that fibrillar insoluble amyloid beta is toxic to cell cultures. Soluble amyloid oligomers that are made of several misfolded units of amyloid beta are also toxic to cells, probably even more than fibrillar.
"There's an interest in finding medications that will quench the deleterious effects of amyloid beta aggregates," he said. "But to create drugs for these, we first need to know how drugs or molecules in general can bind and interact with these fibrils, and this was not well-known. Now we have a better idea of what the molecule needs to interact with these fibrils."
When amyloid peptides fold properly, they hide their hydrophobic residues while exposing their hydrophilic (water-attracting) residues to water. That makes the proteins soluble, Martí said. But when amyloid beta misfolds, it leaves two hydrophobic residues, known as Valine 18 and Phenylalanine 20, exposed to create the hydrophobic cleft.
"It's perfect, because then molecules with hydrophobic domains are driven to bind there," Martí said. "They are compatible with this hydrophobic cleft and associate with the fibril, forming a strong interaction."
If the resulting oxidation keeps the fibrils from aggregating farther into the sticky substance found in the brains of Alzheimer's patients, it may be the start of a useful strategy to stop aggregation before symptoms of the disease appear.
"It's a very attractive system because it uses light, which is a cheap resource," Martí said. "If we can modify complexes so they absorb red light, which is transparent to tissue, we might be able to perform these photochemical modifications in living animals, and maybe someday in humans."
He said light activation allows the researchers to have "exquisite control" of oxidation.
"We imagine it might be possible someday to prevent symptoms of Alzheimer's by targeting amyloid beta in the same way we treat cholesterol in people now to prevent cardiovascular disease," Martí said. "That would be wonderful."
###
Editor's note: Links to high-resolution images for download appear at the end of this release.
Rice alumnus Amir Aliyan, now a postdoctoral researcher at Tarbiat Modares University in Iran, is lead author of the paper. Co-authors are Rice graduate student Bo Jiang, Rice research scientist Christopher Pennington and, from the University of Miami, graduate students Thomas Paul and Gaurav Sharma and Rajeev Prabhakar, an associate professor of chemistry. Martí is an associate professor of chemistry and bioengineering at Rice.
The Welch Foundation and National Science Foundation supported the research. The Center of Computational Science at the University of Miami provided computational resources.
Read the abstract at http://www.cell.com/chem/fulltext/S2451-9294(17)30401-1
DOI: 10.1016/j.chempr.2017.09.011
This news release can be found online at http://news.rice.edu/2017/10/19/discovery-lights-path-for-alzheimers-research/
Follow Rice News and Media Relations via Twitter @RiceUNews
Video:
Video produced by Brandon Martin/Rice University
Related materials:
Angel Martí Group: http://martigroup.rice.edu
The Prabhakar Group: http://umchemistry.cox.miami.edu/prabhakargroup/index.html
Wiess School of Natural Sciences: http://natsci.rice.edu
Images for download:
http://news.rice.edu/files/2017/09/1009_-AMYLOID-1-WEB-1qfeyf3.jpg
A rhenium-based complex developed at Rice University binds to fibrils of misfolded amyloid beta peptide, which marks the location of a hydrophobic cleft that could serve as a drug target, and oxidizes the fibril, which changes its chemistry in a way that could prevent further aggregation. (Credit: Martí Group/Rice University)
http://news.rice.edu/files/2017/10/1009_-AMYLOID-2-WEB-25v75sz.jpg
A metallic probe lights up when it binds to a misfolded amyloid beta peptide in an experiment at Rice University. The probe identified a binding site that could facilitate better drugs to treat Alzheimer's disease. (Credit: Brandon Martin/Rice University)
http://news.rice.edu/files/2017/10/1009_-AMYLOID-3-WEB-201v152.jpg
From left, Rice University research scientist Christopher Pennington, graduate student Bo Jiang and Angel Martí, an associate professor of chemistry and bioengineering, run an amyloid beta experiment in the Martí lab. (Credit: Brandon Martin/Rice University)
http://news.rice.edu/files/2017/10/1009_-AMYLOID-4-WEB-2a067kb.jpg
A metallic probe that binds to amyloid beta peptides offers a way to identify binding sites on the misfolded protein implicated in Alzheimer's disease. When the probe is illuminated with ultraviolet light, it catalyzes oxidation of the protein in a way that might keep it from aggregating in the brains of patients. (Credit: Brandon Martin/Rice University)
Located on a 300-acre forested campus in Houston, Rice University is consistently ranked among the nation's top 20 universities by U.S. News & World Report. Rice has highly respected schools of Architecture, Business, Continuing Studies, Engineering, Humanities, Music, Natural Sciences and Social Sciences and is home to the Baker Institute for Public Policy. With 3,879 undergraduates and 2,861 graduate students, Rice's undergraduate student-to-faculty ratio is 6-to-1. Its residential college system builds close-knit communities and lifelong friendships, just one reason why Rice is ranked No. 1 for quality of life and for lots of race/class interaction and No. 2 for happiest students by the Princeton Review. Rice is also rated as a best value among private universities by Kiplinger's Personal Finance. To read "What they're saying about Rice," go to http://tinyurl.com/RiceUniversityoverview.
Contact:
David Ruth
713-348-6327
david@rice.edu
Mike Williams
713-348-6728
mikewilliams@rice.edu
Journal
Chem